Mira Pharma Leads Healthcare Buzz Surge On Promising Oral Ketamine Analog Preclinical Trial

Shares of Mira Pharmaceuticals gained over 19% on Wednesday, marking their best session in over a month, after the company's oral ketamine analog showed promising data in a preclinical study.

Mira said its Ketamir-2 therapy significantly reduced pain symptoms in rats, with some test animals returning to pre-diabetic sensitivity levels.

The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects, the company added.

On Stocktwits, the news sent 24-hour message volume involving Mira soaring 8,500% by late Wednesday — the highest among all healthcare stocks — with sentiment turning even more 'extremely bullish.'

One watcher expects the stock to cross the $1.2 mark on Thursday easily.

Another said a new 52-week high was imminent.

Mira has already begun dosing and testing Ketamir-2 in a Phase I trial in Israel, which is expected to be completed in the fourth quarter of 2025. 

A Phase IIa trial in diabetic neuropathy is set to begin by the end of 2025, with efficacy data anticipated in early 2026. 

Mira is also developing a topical formulation for localized pain and exploring Ketamir-2's potential in PTSD treatment.

Separately, Mira is progressing with its acquisition of SKNY Pharmaceuticals and sees promise in SKNY-1, a next-generation oral therapy targeting obesity and smoking cessation.

Mira Pharmaceuticals' stock has lost over 8% this year but has risen nearly 29% over the past 12 months.

Shares of the company fell over 11% after-hours on Wednesday, likely due to profit-taking.

For updates and corrections, email newsroom[at]stocktwits[dot]com.